Founder-led sales: a case study playbook for healthcare and life sciences in North America

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in North America. In this market, the North American B2B buyer is saturated with vendor outreach and rewards specificity, category clarity, and speed, so the way you install founder-led sales has to be shaped to that reality from day one.

Names removed, numbers preserved. This is a real founder-led sales engagement, reproduced as a playbook. Client had product-market fit, a rev team of eleven, and a stalled pipeline.

Week one: diagnosis. The stated problem was "not enough leads". The actual problem was hiring VP of Sales at $500k ARR to escape sales, which had been masked by inbound velocity that peaked two quarters earlier.

Weeks two to three: rebuild the target list from scratch and re-cut the trigger. Founder-led sales works when the founder is the fastest feedback loop between market and product; the client had drifted away from that first principle.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in North America it is compounded by the fact that signal above noise, not lead volume is what actually gates growth. Founder-led sales is only useful here when it is pointed at both constraints at once.

Weeks four to six: live at 20% of previous volume, quality bar raised. Founder hours per week in customer conversations moved every week, though absolute numbers stayed modest.

Weeks seven to twelve: ramp. By week ten the number was ahead of the pre-stall baseline. By week twelve it was 40% ahead. Cost per outcome was roughly halved.

What we would repeat: the diagnosis step, the quality bar, and the weekly review. What we would kill sooner: two tools we bought in month one that added noise instead of leverage.

The client's own summary at the end of quarter one: "we thought we needed more of everything; we actually needed less of the wrong things." That is usually the lesson.

Concretely for healthcare and life sciences in North America: the healthcare teams that install this get past procurement instead of dying in it, and the North American teams that install this land inside the first quarter, not the fourth. That is the reason it is worth installing founder-led sales deliberately for this market rather than importing a playbook designed for somewhere else.